Share Price and Basic Stock Data
Last Updated: March 13, 2025, 12:06 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Sun Pharma Advanced Research Company Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 12.8 Cr. | 35.6 | 46.4/26.1 | 3.60 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 37.4 Cr. | 657 | 1,033/506 | 281 | 0.14 % | 1.21 % | 3.57 % | 10.0 | |
| FGP Ltd | 11.1 Cr. | 9.30 | 14.2/5.51 | 48.1 | 3.14 | 0.00 % | 6.46 % | 8.00 % | 10.0 |
| Logica Infoway Ltd | 378 Cr. | 221 | 278/164 | 43.3 | 37.7 | 0.00 % | 14.4 % | 14.2 % | 10.0 |
| CRP Risk Management Ltd | 10.3 Cr. | 5.89 | 30.0/5.89 | 258 | 34.6 | 0.00 % | 0.07 % | 0.07 % | 10.0 |
| Industry Average | 8,281.75 Cr | 254.87 | 101.58 | 107.00 | 0.04% | 21.43% | 23.42% | 9.00 |
All Competitor Stocks of Sun Pharma Advanced Research Company Ltd
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 25 | 28 | 32 | 131 | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 |
| Expenses | 73 | 92 | 107 | 94 | 115 | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 |
| Operating Profit | -11 | -67 | -78 | -63 | 16 | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 |
| OPM % | -18% | -264% | -275% | -198% | 12% | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 |
| Interest | 2 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -16 | -71 | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -16 | -71 | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 |
| EPS in Rs | -0.60 | -2.61 | -3.03 | -2.52 | 0.37 | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 |
Last Updated: March 4, 2025, 3:14 pm
Below is a detailed analysis of the quarterly data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹15.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Sep 2024) to ₹15.00 Cr., marking an increase of ₹2.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹89.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 117.00 Cr. (Sep 2024) to ₹89.00 Cr., marking a decrease of 28.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹-74.00 Cr.. The value appears strong and on an upward trend. It has increased from -104.00 Cr. (Sep 2024) to ₹-74.00 Cr., marking an increase of ₹30.00 Cr..
- For OPM %, as of Dec 2024, the value is -499.00%. The value appears strong and on an upward trend. It has increased from -808.00% (Sep 2024) to -499.00%, marking an increase of 309.00%.
- For Other Income, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Dec 2024, the value is ₹3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Sep 2024) to ₹3.00 Cr., marking an increase of ₹2.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹3.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 3.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹-80.00 Cr.. The value appears strong and on an upward trend. It has increased from -108.00 Cr. (Sep 2024) to ₹-80.00 Cr., marking an increase of ₹28.00 Cr..
- For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
- For Net Profit, as of Dec 2024, the value is ₹-80.00 Cr.. The value appears strong and on an upward trend. It has increased from -108.00 Cr. (Sep 2024) to ₹-80.00 Cr., marking an increase of ₹28.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is -2.46. The value appears strong and on an upward trend. It has increased from ₹-3.32 (Sep 2024) to -2.46, marking an increase of 0.86.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 2:44 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 87 | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 239 | 76 | 61 |
| Expenses | 104 | 134 | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 453 | 479 | 442 |
| Operating Profit | -17 | 34 | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -214 | -404 | -381 |
| OPM % | -19% | 20% | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -90% | -534% | -623% |
| Other Income | 2 | 10 | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 11 | 29 | 6 |
| Interest | 4 | 6 | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 8 | 2 | 5 |
| Depreciation | 3 | 4 | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 12 | 12 | 11 |
| Profit before tax | -22 | 34 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -391 |
| Tax % | 0% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -22 | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -391 |
| EPS in Rs | -0.91 | 1.23 | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -6.86 | -11.96 | -12.05 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 236.36% | -233.33% | -75.00% | -70.00% | -65.55% | 26.40% | -115.17% | 51.60% | -34.44% | -9.85% | -73.99% |
| Change in YoY Net Profit Growth (%) | 0.00% | -469.70% | 158.33% | 5.00% | 4.45% | 91.94% | -141.57% | 166.77% | -86.04% | 24.58% | -64.14% |
Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -16% |
| 3 Years: | -33% |
| TTM: | -43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 1% |
| 3 Years: | -24% |
| 1 Year: | -66% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -122% |
Last Updated: Unknown
Balance Sheet
Last Updated: February 12, 2025, 2:46 pm
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 32 | 32 |
| Reserves | 85 | 116 | 76 | 8 | 133 | 160 | 270 | -45 | -194 | 4 | 480 | 92 |
| Borrowings | 81 | 5 | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 16 | 56 |
| Other Liabilities | 20 | 39 | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 170 | 302 | 305 |
| Total Liabilities | 209 | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 |
| Fixed Assets | 66 | 64 | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 106 | 103 |
| CWIP | 0 | 1 | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 27 | 44 |
| Investments | 97 | 6 | -0 | -0 | 10 | 108 | 211 | 8 | 6 | 12 | 291 | 2 |
| Other Assets | 46 | 112 | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 406 | 338 |
| Total Assets | 209 | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 |
Below is a detailed analysis of the balance sheet data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2024, the value is ₹32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded ₹32.00 Cr..
- For Reserves, as of Mar 2024, the value is ₹92.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹480.00 Cr. (Mar 2023) to ₹92.00 Cr., marking a decrease of 388.00 Cr..
- For Borrowings, as of Mar 2024, the value is ₹56.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹16.00 Cr. (Mar 2023) to ₹56.00 Cr., marking an increase of 40.00 Cr..
- For Other Liabilities, as of Mar 2024, the value is ₹305.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹302.00 Cr. (Mar 2023) to ₹305.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2024, the value is ₹486.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹830.00 Cr. (Mar 2023) to ₹486.00 Cr., marking a decrease of 344.00 Cr..
- For Fixed Assets, as of Mar 2024, the value is ₹103.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹106.00 Cr. (Mar 2023) to ₹103.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Mar 2024, the value is ₹44.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹27.00 Cr. (Mar 2023) to ₹44.00 Cr., marking an increase of 17.00 Cr..
- For Investments, as of Mar 2024, the value is ₹2.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹291.00 Cr. (Mar 2023) to ₹2.00 Cr., marking a decrease of 289.00 Cr..
- For Other Assets, as of Mar 2024, the value is ₹338.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹406.00 Cr. (Mar 2023) to ₹338.00 Cr., marking a decrease of 68.00 Cr..
- For Total Assets, as of Mar 2024, the value is ₹486.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹830.00 Cr. (Mar 2023) to ₹486.00 Cr., marking a decrease of 344.00 Cr..
Notably, the Reserves (₹92.00 Cr.) exceed the Borrowings (56.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -98.00 | 29.00 | -39.00 | -119.00 | -126.00 | -245.00 | -153.00 | -377.00 | -371.00 | -266.00 | -230.00 | -460.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 |
| Working Capital Days | 72 | 129 | 21 | -42 | -59 | -232 | -98 | -557 | -96 | -97 | -189 | -509 |
| ROCE % | -20% | 21% | -32% | -71% | -94% | -143% | -62% | -183% | -242% | -218% | -67% | -109% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 595,869 | 0.13 | 17.09 | 595,869 | 2025-03-11 | 0% |
| ITI Pharma and Healthcare Fund | 58,628 | 1.17 | 1.68 | 595,869 | 2025-03-11 | -90.16% |
| Nippon India Nifty Smallcap 250 Index Fund | 48,528 | 0.14 | 1.39 | 595,869 | 2025-03-11 | -91.86% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 30,326 | 0.14 | 0.87 | 595,869 | 2025-03-11 | -94.91% |
| SBI Nifty Smallcap 250 Index Fund | 23,805 | 0.14 | 0.68 | 595,869 | 2025-03-11 | -96% |
| ICICI Prudential Nifty Smallcap 250 Index Fund | 11,330 | 0.14 | 0.32 | 595,869 | 2025-03-11 | -98.1% |
| HDFC NIFTY Smallcap 250 ETF | 6,573 | 0.14 | 0.19 | 595,869 | 2025-03-11 | -98.9% |
| HDFC Nifty Smallcap 250 Index Fund | 5,301 | 0.14 | 0.15 | 595,869 | 2025-03-11 | -99.11% |
| Motilal Oswal Nifty 500 Index Fund | 3,060 | 0.01 | 0.09 | 595,869 | 2025-03-11 | -99.49% |
| Edelweiss Nifty Smallcap 250 Index Fund | 1,234 | 0.14 | 0.04 | 595,869 | 2025-03-11 | -99.79% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | -11.93 | -7.82 |
| Diluted EPS (Rs.) | -11.93 | -7.82 |
| Cash EPS (Rs.) | -11.55 | -6.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3.88 | 15.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3.88 | 15.80 |
| Revenue From Operations / Share (Rs.) | 2.33 | 7.36 |
| PBDIT / Share (Rs.) | -11.48 | -6.26 |
| PBIT / Share (Rs.) | -11.87 | -6.62 |
| PBT / Share (Rs.) | -11.92 | -6.86 |
| Net Profit / Share (Rs.) | -11.93 | -6.86 |
| NP After MI And SOA / Share (Rs.) | -11.93 | -6.86 |
| PBDIT Margin (%) | -493.24 | -85.09 |
| PBIT Margin (%) | -509.80 | -90.01 |
| PBT Margin (%) | -512.05 | -93.21 |
| Net Profit Margin (%) | -512.55 | -93.21 |
| NP After MI And SOA Margin (%) | -512.55 | -93.21 |
| Return on Networth / Equity (%) | -307.91 | -43.40 |
| Return on Capital Employeed (%) | -154.06 | -33.00 |
| Return On Assets (%) | -75.18 | -26.81 |
| Total Debt / Equity (X) | 0.37 | 0.00 |
| Asset Turnover Ratio (%) | 0.11 | 0.00 |
| Current Ratio (X) | 1.02 | 2.54 |
| Quick Ratio (X) | 1.02 | 2.54 |
| Interest Coverage Ratio (X) | -219.89 | -26.61 |
| Interest Coverage Ratio (Post Tax) (X) | -227.50 | -28.15 |
| Enterprise Value (Cr.) | 11897.66 | 5712.17 |
| EV / Net Operating Revenue (X) | 157.49 | 23.92 |
| EV / EBITDA (X) | -31.93 | -28.11 |
| MarketCap / Net Operating Revenue (X) | 158.92 | 24.39 |
| Price / BV (X) | 95.47 | 11.36 |
| Price / Net Operating Revenue (X) | 158.93 | 24.39 |
| EarningsYield | -0.03 | -0.03 |
After reviewing the key financial ratios for Sun Pharma Advanced Research Company Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -11.93. This value is below the healthy minimum of 5. It has decreased from -7.82 (Mar 23) to -11.93, marking a decrease of 4.11.
- For Diluted EPS (Rs.), as of Mar 24, the value is -11.93. This value is below the healthy minimum of 5. It has decreased from -7.82 (Mar 23) to -11.93, marking a decrease of 4.11.
- For Cash EPS (Rs.), as of Mar 24, the value is -11.55. This value is below the healthy minimum of 3. It has decreased from -6.50 (Mar 23) to -11.55, marking a decrease of 5.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 3.88. It has decreased from 15.80 (Mar 23) to 3.88, marking a decrease of 11.92.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 3.88. It has decreased from 15.80 (Mar 23) to 3.88, marking a decrease of 11.92.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 2.33. It has decreased from 7.36 (Mar 23) to 2.33, marking a decrease of 5.03.
- For PBDIT / Share (Rs.), as of Mar 24, the value is -11.48. This value is below the healthy minimum of 2. It has decreased from -6.26 (Mar 23) to -11.48, marking a decrease of 5.22.
- For PBIT / Share (Rs.), as of Mar 24, the value is -11.87. This value is below the healthy minimum of 0. It has decreased from -6.62 (Mar 23) to -11.87, marking a decrease of 5.25.
- For PBT / Share (Rs.), as of Mar 24, the value is -11.92. This value is below the healthy minimum of 0. It has decreased from -6.86 (Mar 23) to -11.92, marking a decrease of 5.06.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -11.93. This value is below the healthy minimum of 2. It has decreased from -6.86 (Mar 23) to -11.93, marking a decrease of 5.07.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -11.93. This value is below the healthy minimum of 2. It has decreased from -6.86 (Mar 23) to -11.93, marking a decrease of 5.07.
- For PBDIT Margin (%), as of Mar 24, the value is -493.24. This value is below the healthy minimum of 10. It has decreased from -85.09 (Mar 23) to -493.24, marking a decrease of 408.15.
- For PBIT Margin (%), as of Mar 24, the value is -509.80. This value is below the healthy minimum of 10. It has decreased from -90.01 (Mar 23) to -509.80, marking a decrease of 419.79.
- For PBT Margin (%), as of Mar 24, the value is -512.05. This value is below the healthy minimum of 10. It has decreased from -93.21 (Mar 23) to -512.05, marking a decrease of 418.84.
- For Net Profit Margin (%), as of Mar 24, the value is -512.55. This value is below the healthy minimum of 5. It has decreased from -93.21 (Mar 23) to -512.55, marking a decrease of 419.34.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -512.55. This value is below the healthy minimum of 8. It has decreased from -93.21 (Mar 23) to -512.55, marking a decrease of 419.34.
- For Return on Networth / Equity (%), as of Mar 24, the value is -307.91. This value is below the healthy minimum of 15. It has decreased from -43.40 (Mar 23) to -307.91, marking a decrease of 264.51.
- For Return on Capital Employeed (%), as of Mar 24, the value is -154.06. This value is below the healthy minimum of 10. It has decreased from -33.00 (Mar 23) to -154.06, marking a decrease of 121.06.
- For Return On Assets (%), as of Mar 24, the value is -75.18. This value is below the healthy minimum of 5. It has decreased from -26.81 (Mar 23) to -75.18, marking a decrease of 48.37.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.37. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.37, marking an increase of 0.37.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.11. It has increased from 0.00 (Mar 23) to 0.11, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 24, the value is 1.02. This value is below the healthy minimum of 1.5. It has decreased from 2.54 (Mar 23) to 1.02, marking a decrease of 1.52.
- For Quick Ratio (X), as of Mar 24, the value is 1.02. This value is within the healthy range. It has decreased from 2.54 (Mar 23) to 1.02, marking a decrease of 1.52.
- For Interest Coverage Ratio (X), as of Mar 24, the value is -219.89. This value is below the healthy minimum of 3. It has decreased from -26.61 (Mar 23) to -219.89, marking a decrease of 193.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -227.50. This value is below the healthy minimum of 3. It has decreased from -28.15 (Mar 23) to -227.50, marking a decrease of 199.35.
- For Enterprise Value (Cr.), as of Mar 24, the value is 11,897.66. It has increased from 5,712.17 (Mar 23) to 11,897.66, marking an increase of 6,185.49.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 157.49. This value exceeds the healthy maximum of 3. It has increased from 23.92 (Mar 23) to 157.49, marking an increase of 133.57.
- For EV / EBITDA (X), as of Mar 24, the value is -31.93. This value is below the healthy minimum of 5. It has decreased from -28.11 (Mar 23) to -31.93, marking a decrease of 3.82.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 158.92. This value exceeds the healthy maximum of 3. It has increased from 24.39 (Mar 23) to 158.92, marking an increase of 134.53.
- For Price / BV (X), as of Mar 24, the value is 95.47. This value exceeds the healthy maximum of 3. It has increased from 11.36 (Mar 23) to 95.47, marking an increase of 84.11.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 158.93. This value exceeds the healthy maximum of 3. It has increased from 24.39 (Mar 23) to 158.93, marking an increase of 134.54.
- For EarningsYield, as of Mar 24, the value is -0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded -0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharma Advanced Research Company Ltd:
- Net Profit Margin: -512.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -154.06% (Industry Average ROCE: 21.43%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -307.91% (Industry Average ROE: 23.42%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -227.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 101.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.37
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -512.55%
About the Company - Qualitative Analysis
Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837. Currently Company is involved in the business activities of Research and experimental development on natural sciences and engineering. Company's Total Operating Revenue is Rs. 75.55 Cr. and Equity Capital is Rs. 32.45 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Vadodra District Gujarat 391775 | secretarial@sparcmail.com http://www.sparc.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dilip S Shanghvi | Chairman & Non-Exe.Director |
| Dr. T Rajamannar | Non Executive Director |
| Dr. Robert J Spiegel | Independent Director |
| Mr. Sudhir V Valia | Non Executive Director |
| Ms. Bhavna Doshi | Independent Director |
| Dr. Ferzaan Engineer | Independent Director |
| Ms. Vidhi Shanghvi | Non Exe.Non Ind.Director |
FAQ
What is the latest intrinsic value of Sun Pharma Advanced Research Company Ltd?
The latest intrinsic value of Sun Pharma Advanced Research Company Ltd as on 13 March 2025 is 57.49, which is 53.64% lower than the current market price of ₹124.00, indicating the stock is overvalued by 53.64%. The intrinsic value of Sun Pharma Advanced Research Company Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹4,024 Cr. and recorded a high/low of ₹474/109 during the current fiscal year 2024-2025. As of Mar 2024, the company has reserves of ₹92 Cr and total liabilities of ₹486 Cr.
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
The Market Cap of Sun Pharma Advanced Research Company Ltd is 4,024 Cr..
What is the current Stock Price of Sun Pharma Advanced Research Company Ltd as on 13 March 2025?
The current stock price of Sun Pharma Advanced Research Company Ltd as on 13 March 2025 is ₹124.
What is the High / Low of Sun Pharma Advanced Research Company Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Sun Pharma Advanced Research Company Ltd stocks is ₹474/109.
What is the Stock P/E of Sun Pharma Advanced Research Company Ltd?
The Stock P/E of Sun Pharma Advanced Research Company Ltd is .
What is the Book Value of Sun Pharma Advanced Research Company Ltd?
The Book Value of Sun Pharma Advanced Research Company Ltd is 3.85.
What is the Dividend Yield of Sun Pharma Advanced Research Company Ltd?
The Dividend Yield of Sun Pharma Advanced Research Company Ltd is 0.00 %.
What is the ROCE of Sun Pharma Advanced Research Company Ltd?
The ROCE of Sun Pharma Advanced Research Company Ltd is 109 %.
What is the ROE of Sun Pharma Advanced Research Company Ltd?
The ROE of Sun Pharma Advanced Research Company Ltd is 122 %.
What is the Face Value of Sun Pharma Advanced Research Company Ltd?
The Face Value of Sun Pharma Advanced Research Company Ltd is 1.00.